Niedmann, Paul Dieter

[["dc.bibliographiccitation.firstpage","269"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neurosciences"],["dc.bibliographiccitation.lastpage","271"],["dc.bibliographiccitation.volume","251"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Schenk-Daprá, Bettina"],["dc.contributor.author","Stiens, Gerthild"],["dc.contributor.author","Bleich, Stefan"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Müller, Peter"],["dc.contributor.author","Niedmann, Paul Dieter"],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Rüther, Eckart"],["dc.date.accessioned","2017-09-07T11:44:42Z"],["dc.date.available","2017-09-07T11:44:42Z"],["dc.date.issued","2006"],["dc.description.abstract","Objective The goal of this study was to identify adverse effects of the atypical neuroleptic clozapine on liver function and lipid metabolism. Methods Data which included serum levels of clozapine and its hepatic metabolite N-desmethyl clozapine were collected from medical records of patients treated with clozapine and controls. Results We identified a clozapine-associated marked elevation of plasma cholinesterase (ChE) with unchanged levels of AST, ALT or g-GT. ChE was correlated to the serum level of clozapine and even closer to N-desmethyl clozapine. For the total patient group we observed significant correlations of ChE with the body-mass index and body weight. However, clozapine-treated patients and controls did not differ with regard to body-mass index, triglycerides, and cholesterol. Conclusion We report for the first time a clozapine-associated and dose-dependent elevation of plasma ChE, which may be related to clozapine-associated effects on hepatic lipid metabolism or ChE enzyme induction."],["dc.identifier.doi","10.1007/pl00007544"],["dc.identifier.gro","3151720"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8541"],["dc.language.iso","en"],["dc.notes.status","public"],["dc.notes.submitter","chake"],["dc.relation.issn","0940-1334"],["dc.title","Clozapine-associated elevation of plasma cholinesterase"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","107"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Clinical Biochemistry"],["dc.bibliographiccitation.lastpage","113"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Wieland, Eberhard"],["dc.contributor.author","Shipkova, Maria"],["dc.contributor.author","Schellhaas, Ulrike"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Niedmann, Paul Dieter"],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Oellerich, Michael"],["dc.date.accessioned","2021-06-01T10:50:05Z"],["dc.date.available","2021-06-01T10:50:05Z"],["dc.date.issued","2000"],["dc.description.abstract","Objectives: We have identified an acyl glucuronide (M-2) of the immunosuppressant mycophenolic acid (MPA). Acyl glucuronides have toxic potential and may contribute to drug toxicity. Whether acyl glucuronides are able to induce release of proinflammatory cytokines is unknown. Gastrointestinal disturbances have been observed during MPA therapy and may involve an inflammatory reaction. This study investigated whether M-2 can induce IL-6 and TNF-alpha release as well as gene expression of these cytokines in leukocytes. Design and methods: M-2 was produced by incubation of MPA with human liver microsomes. Human mononuclear leukocytes were incubated in the presence of M-2. Concentrations of IL-6 and TNF-alpha were measured by ELISA. Expression of mRNA was determined by quantitative RT-PCR. Results: Incubation of 3 x 10(6) cells with M-2 resulted in a time and dose dependent release of cytokines, whereas MPA or its phenolic glucuronide MPAG were without effect. Cytokine liberation depended on mRNA induction. Response to M-2 showed much inter individual variability (30-fold for IL-6, 3-fold for TNF-alpha). Conclusions: If M-2 promotes release of cytokines in vivo, these may mediate some of the toxic actions of MPA. Copyright (C) 2000 The Canadian Society of Clinical Chemists."],["dc.identifier.doi","10.1016/S0009-9120(99)00101-0"],["dc.identifier.isi","000086461900005"],["dc.identifier.pmid","10751588"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86520"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0009-9120"],["dc.title","Induction of cytokine release by the acyl glucuronide of mycophenolic acid: A link to side effects?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","53"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Clinical Biochemistry"],["dc.bibliographiccitation.lastpage","57"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Wieland, Eberhard"],["dc.contributor.author","Shipkova, Maria"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Braun, Felix"],["dc.contributor.author","Niedmann, Paul-Dieter"],["dc.contributor.author","Armstrong, Victor W."],["dc.contributor.author","Ringe, Burckhardt"],["dc.contributor.author","Svinarov, Dobrin A."],["dc.contributor.author","Oellerich, Michael"],["dc.date.accessioned","2021-06-01T10:50:04Z"],["dc.date.available","2021-06-01T10:50:04Z"],["dc.date.issued","2001"],["dc.description.abstract","Objectives: Little is known about the effect of ischemia/reperfusion with xenogenic blood on function and gene expression of CYP3A4, the enzyme largely responsible for the metabolism of the immunosuppressants Cyclosporin A (CsA) and Tacrolimus. Design and methods: In a pig liver perfusion model, we have compared the effect of perfusion (3 h) after 20 h cold storage, with either pig or human blood on CsA metabolism and CYP3A4-mRNA expression. CYP3A4-mRNA was quantified by RT-PCR, CsA and its major metabolites AM1, AM9, AM4N by RP-HPLC. IL-6 served as inflammation marker, GLDH and ALT to estimate tissue damage. Results: Inflammatory response and tissue damage were more extensive during xenoperfusion. CYP3A4 expression decreased similarly during xenogenic and allogenic perfusion. CsA conversion to its metabolites was also comparable during xeno- and alloperfusion. Conclusion: There is no evidence that during the early reperfusion period pig liver CYP3A4 is severely affected if the organ is xenoperfused with human blood in comparison with alloperfusion. (C) 2001 The Canadian Society of Clinical Chemists. All rights reserved."],["dc.identifier.doi","10.1016/S0009-9120(00)00203-4"],["dc.identifier.isi","000169234600010"],["dc.identifier.pmid","11239516"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86518"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.publisher.place","Oxford"],["dc.relation.conference","Analytical Conference 2000"],["dc.relation.eventlocation","MUNICH, GERMANY"],["dc.relation.issn","0009-9120"],["dc.title","Preliminary report on the effect of xenoperfusion with human blood on cyclosporin A metabolism and cytochrome-P-4503A4-mRNA expression in a pig liver perfusion model"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Berger, C."],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Mayer, G."],["dc.contributor.author","Niedmann, P."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Bleich, Stefan"],["dc.date.accessioned","2018-11-07T10:36:46Z"],["dc.date.available","2018-11-07T10:36:46Z"],["dc.date.issued","2003"],["dc.identifier.isi","000186262800150"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45404"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","23rd Symposium of the Arbeitsgemeinschaft-Neuropsychopharmakologie-und-Pharmakopsychiatrie (AGNP)"],["dc.relation.eventlocation","MUNICH, GERMANY"],["dc.title","Serum homocysteine in obstructive sleep apnea syndrome can be lowered by CPAP-therapy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","204"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Dementia and Geriatric Cognitive Disorders"],["dc.bibliographiccitation.lastpage","206"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Schmidt, H."],["dc.contributor.author","Otto, Markus"],["dc.contributor.author","Niedmann, P."],["dc.contributor.author","Cepek, L."],["dc.contributor.author","Schroter, A."],["dc.contributor.author","Kretzschmar, Hans A."],["dc.contributor.author","Poser, Sigrid"],["dc.date.accessioned","2018-11-07T10:52:21Z"],["dc.date.available","2018-11-07T10:52:21Z"],["dc.date.issued","2004"],["dc.description.abstract","The diagnosis of Creutzfeldt- Jakob disease (CJD) is still made by exclusion of other dementias. We now evaluated lactate dehydrogenase (LDH) in the cerebrospinal fluid (CSF) as a possible additional diagnostic tool. CSF LDH levels of patients with CJD ( n = 26) were compared with those in other dementias ( n = 28). LDH isoenzymes were determined in a subset ( n = 9). Total LDH and isoenzyme LDH-1 were significantly higher, whereas the fractions of LDH-2 and LDH-3 were significantly lower in CJD patients. We conclude that in addition to established CSF parameters, LDH and its isoenzymes might serve as a further help to discriminate between CJD and other dementias. Copyright (C) 2004 S. Karger AG, Basel."],["dc.identifier.doi","10.1159/000076357"],["dc.identifier.isi","000220084000016"],["dc.identifier.pmid","14739545"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49094"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1420-8008"],["dc.title","CSF lactate dehydrogenase activity in patients with Creutzfeldt-Jakob disease exceeds that in other dementias"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Niedmann, P."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Kropp, Silke"],["dc.date.accessioned","2018-11-07T08:45:58Z"],["dc.date.available","2018-11-07T08:45:58Z"],["dc.date.issued","2005"],["dc.identifier.isi","000227108700031"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20579"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","International Meeting on Pharmacovigilance in Psychiatry, Therapetic Drug Monitoring and Pharmacognetics of Psychotropic Drugs"],["dc.relation.eventlocation","Lausanne, SWITZERLAND"],["dc.title","Plasma prolactin levels during treatment with olanzapine"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","351"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Alcohol and Alcoholism"],["dc.bibliographiccitation.lastpage","354"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Bleich, S."],["dc.contributor.author","Degner, D."],["dc.contributor.author","Wiltfang, J."],["dc.contributor.author","Maler, J. M."],["dc.contributor.author","Niedmann, P."],["dc.contributor.author","Cohrs, S."],["dc.contributor.author","Mangholz, A."],["dc.contributor.author","Porzig, J."],["dc.contributor.author","Sprung, R."],["dc.contributor.author","Rüther, E."],["dc.contributor.author","Kornhuber, J."],["dc.date.accessioned","2017-09-07T11:44:44Z"],["dc.date.available","2017-09-07T11:44:44Z"],["dc.date.issued","2000"],["dc.description.abstract","Ethanol exerts its behavioural effects largely by interacting with receptors for brain neurotransmitters. However, the molecular mechanisms involving these interactions and the pathogenesis of alcohol-withdrawal symptomatology are still not well understood. Until recently, no data were available about homocysteine (Hcy) levels in acute alcohol intoxication of chronic alcoholics and in patients undergoing withdrawal from alcohol. Hcy, blood-alcohol concentrations, vitamins B6, B12, and folate concentrations were assessed in 29 chronic alcoholics, who underwent withdrawal from alcohol. We observed increased Hcy levels in most patients. Hcy levels steadily decreased during the observation period. We postulate that hyperhomocysteinaemia and excitatory amino acid neurotransmitters, by their agonism at the N-methyl-d-aspartate receptor, may partly mediate alcohol-associated withdrawal symptomatology. The importance of assessing serum Hcy levels in order to detect methylation deficiency in patients with chronic alcoholism and for possible therapeutic strategies is discussed."],["dc.identifier.doi","10.1093/alcalc/35.4.351"],["dc.identifier.gro","3151736"],["dc.identifier.pmid","10905999"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8557"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","chake"],["dc.relation.issn","1464-3502"],["dc.title","Elevated Homocysteine Levels in Alcohol Withdrawal"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]